A multimodal approach to accelerate drug discovery and development in Alzheimer’s disease

Project description

Combining genetics and imaging for AD drug discovery

Clinical trials on new drugs against Alzheimer's disease (AD) have failed to show any efficacy in slowing disease progression, underscoring the importance of new therapeutic targets. Towards this goal, the EU-funded MAP-AD project will use autosomal and X chromosome genetic variants to identify novel molecular pathways and putative therapeutic targets. Scientists will decipher the impact of specific genetic variants on gene expression through the analysis of post-mortem brain tissue. Combined with multimodal brain imaging analysis, the genomics information will be applied to correctly enrol patients in clinical trials expediting the development of drugs for the prevention and treatment of AD.

Fields of science

• natural sciences › computer and information sciences › data science › data analysis
• medical and health sciences › basic medicine › neurology › alzheimer
• natural sciences › computer and information sciences › data science › big data

Programme(s)

• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2019 - Individual Fellowships

Call for proposal

H2020-MSCA-IF-2019
See other projects for this call

Funding Scheme

MSCA-IF-GF - Global Fellowships

Coordinator

INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE

Address

Boulevard De L'hopital 47
75013 Paris
France

Activity type

Research Organisations

EU contribution

€ 257 619,84

Partners (1)

BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

United States

Address

Serra Mall 450
94305 2004 Stanford

Activity type

Higher or Secondary Education Establishments